# A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma

> **NCT03786419** · PHASE2 · WITHDRAWN · sponsor: **Health Pharma Professional Research**

## Conditions studied

- Malignant Pleural Mesothelioma, Advanced
- Malignant Pleural Mesothelioma, Unresectable

## Interventions

- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT03786419
- **Lead sponsor:** Health Pharma Professional Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-08
- **Primary completion:** 2020-08
- **Final completion:** 2020-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Publication of study results of ICI use in MPM as first line therapy
- **Last updated:** 2021-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03786419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03786419, "A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03786419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*